-
Product Insights
Histamine H3 Receptor – Drugs In Development, 2023
Global Markets Direct’s Histamine H3 Receptor provides in depth analysis on Histamine H3 Receptor targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Histamine H3 Receptor targeted therapeutics...
-
Product Insights
Qidong H3 Offshore Wind Farm
Qidong H3 Offshore Wind Farm is an offshore wind project located in Yellow Sea, China. The project is owned by Jiangsu Huawei Wind Power Co Ltd; Qidong Huaerrui Wind Power Technology Co Ltd and was developed by Qidong Huaerrui Wind Power Technology Co Ltd. The project came online in 2021. Empower your strategies with our Qidong H3 Offshore Wind Farm report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The...
-
Product Insights
Shengdong Rudong H3 Offshore Wind Farm
Shengdong Rudong H3 Offshore Wind Farm is an offshore wind project located in East China Sea, China. The project is owned by CSSC Haizhuang (Beijing) New Energy Investment Co Ltd; Huaneng Power International Inc and was developed by Huaneng Shengdong Rudong Offshore Wind Power Co Ltd. The project came online in 2020. Empower your strategies with our Shengdong Rudong H3 Offshore Wind Farm report and make more profitable business decisions. Note: This is an on-demand report that will be delivered...
-
Product Insights
SPIC Jigansu Dafeng H3 Offshore Wind Farm
SPIC Jigansu Dafeng H3 Offshore Wind Farm is an offshore wind project located in East China Sea, China. The project is owned by State Power Investment Corp Ltd and was developed by China Power Investment Corp. The project came online in 2018. Empower your strategies with our SPIC Jigansu Dafeng H3 Offshore Wind Farm report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2...
-
Product Insights
Sheyang Offshore South Area H3 Wind Power Project
Jiangsu Sheyang Yancheng South Area H3 Wind Farm is an offshore wind project located in Yellow Sea, China. The project is owned and being developed by Hebei Jiantou Offshore Wind Power Sheyang Co Ltd. The project is at the permitting stage. Empower your strategies with our Jiangsu Sheyang Yancheng South Area H3 Wind Farm report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ifinatamab Deruxtecan in Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ifinatamab Deruxtecan in Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ifinatamab Deruxtecan in Breast Cancer Drug Details: Ifinatamab deruxtecan (DS-7300) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ifinatamab Deruxtecan in Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ifinatamab Deruxtecan in Melanoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ifinatamab Deruxtecan in Melanoma Drug Details: Ifinatamab deruxtecan (DS-7300) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ifinatamab Deruxtecan in Bladder Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ifinatamab Deruxtecan in Bladder Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ifinatamab Deruxtecan in Bladder Cancer Drug Details: Ifinatamab deruxtecan (DS-7300) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ifinatamab Deruxtecan in Sarcomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ifinatamab Deruxtecan in Sarcomas report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ifinatamab Deruxtecan in Sarcomas Drug Details: Ifinatamab deruxtecan (DS-7300) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ifinatamab Deruxtecan in Endometrial Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ifinatamab Deruxtecan in Endometrial Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ifinatamab Deruxtecan in Endometrial Cancer Drug Details: Ifinatamab deruxtecan (DS-7300) is...